Stock Analysis

ezCaretech Second Quarter 2025 Earnings: EPS: ₩134 (vs ₩95.00 in 2Q 2024)

KOSDAQ:A099750
Source: Shutterstock

ezCaretech (KOSDAQ:099750) Second Quarter 2025 Results

Key Financial Results

  • Revenue: ₩18.7b (up 11% from 2Q 2024).
  • Net income: ₩901.8m (up 41% from 2Q 2024).
  • Profit margin: 4.8% (up from 3.8% in 2Q 2024). The increase in margin was driven by higher revenue.
  • EPS: ₩134 (up from ₩95.00 in 2Q 2024).
earnings-and-revenue-history
KOSDAQ:A099750 Earnings and Revenue History November 14th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

ezCaretech shares are down 3.3% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for ezCaretech that you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KOSDAQ:A099750

ezCaretech

A medical IT professional technology company, engages in the provision of various modules for hospital operations in South Korea, Saudi Arabia, the United States, Japan, and internationally.

Flawless balance sheet with acceptable track record.